Supplemental online content for:

**Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis**

Victoria S. Blinder, MD; Elizabeth Garrett-Mayer, PhD; Paul B. Jacobsen, PhD; Mary May Kozlik, CPHQ; Merry Jennifer Markham, MD; Robert D. Siegel, MD; Arif H. Kamal, MD, MHS, MBA; Stephanie T.S. Crist, RN, BSN, MHSA; Jon Rosenthal, MS, MBA; and Anne C. Chiang, MD, PhD; on behalf of the ASCO Quality Publications Task Force

*J Natl Compr Canc Netw* 2022;20(10):1099–1106.e2

-eFigure 1: Summary of Composite Measure
-eTable 1: Distribution of Performance on Medication Adherence Addressed
-eAppendix 1: Members of the ASCO Quality Publications Task Force
Oral chemo monitor on visit/contact (a–b) N=141

**eFigure 1.** Summary of composite measure (medication adherence assessed and addressed) (n = 141; 25th percentile: 30.8%; median: 64.5%; 75th percentile: 92.3%).
Abbreviation: chemo, chemotherapy.

**eTable 1. Distribution of Performance on Medication Adherence Addressed**

<table>
<thead>
<tr>
<th>Performance</th>
<th>0%</th>
<th>33%–67%</th>
<th>100%</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 chart</td>
<td>11</td>
<td>31</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>2 charts</td>
<td>2</td>
<td>2</td>
<td>11</td>
<td>15</td>
</tr>
<tr>
<td>3 charts</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>4 charts</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>13</td>
<td>4</td>
<td>45</td>
<td>62</td>
</tr>
</tbody>
</table>
eAppendix 1. Members of the ASCO Quality Publications Task Force

Linda D. Bosserman, MD1; Ronald C. Chen, MD, MPH2; Inga T. Lennes, MD, MPH, MBA3; Issam Makhoul, MD4; Steve Power, MBA5; Gabrielle B. Rocque, MD6; Charles L. Shapiro, MD7; and Meghan Underhill, BSN, NP, PhD8

1City of Hope, Rancho Cucamonga, California
2University of Kansas, Kansas City, Kansas
3Massachusetts General Hospital Cancer Center, Boston, Massachusetts
4University of Arkansas for Medical Sciences, Little Rock, Arkansas
5Duke Cancer Institute, Durham, North Carolina
6University of Alabama at Birmingham, Birmingham, Alabama
7Icahn School of Medicine at Mt Sinai, New York, New York
8Dana-Farber Cancer Institute, Boston, Massachusetts